Dongkook Pharmaceutical Co Ltd represents a commitment to improving healthcare and enhancing people's lives. Their corporate philosophy revolves around innovation, integrity, and customer-centricity. As a leading pharmaceutical company, Dongkook focuses on developing high-quality products and delivering exceptional services to meet the diverse needs of patients and healthcare professionals. With a strong emphasis on research and development, Dongkook Pharmaceutical Co Ltd continuously strives to contribute to advancements in the medical field. Through its unwavering dedication to excellence and putting customers at the forefront, Dongkook Pharmaceutical Co Ltd remains a trusted and respected name in the industry.

Dongkook Pharmaceutical Co Ltd is primarily present in South Korea.

Dongkook Pharmaceutical Co Ltd has achieved several significant milestones in its operation. The company has successfully established itself as a leading player in the pharmaceutical industry, both domestically and internationally. Dongkook Pharmaceutical Co Ltd has shown remarkable growth and innovation over the years, launching a wide range of high-quality healthcare products and medications. Additionally, the company has received numerous certifications and accolades for its commitment to excellence and adherence to stringent quality standards. With its relentless focus on research and development, Dongkook Pharmaceutical Co Ltd continues to make strides towards providing effective and efficient healthcare solutions to its customers worldwide.

Dongkook Pharmaceutical Co Ltd, a leading company in the pharmaceutical industry, has a rich history and background. Established in [year], Dongkook Pharmaceutical has been dedicated to improving people's health and well-being through innovative solutions. With a strong focus on research and development, the company has successfully launched a diverse range of pharmaceutical products that are trusted by both medical professionals and patients worldwide. Dongkook Pharmaceutical's commitment to quality, excellence, and customer satisfaction has made it a renowned player in the industry. With its continuous growth and expansion, Dongkook Pharmaceutical Co Ltd aims to enhance the quality of life for individuals globally.

Dongkook Pharmaceutical Co Ltd faces competition from several key players in the market. Some notable competitors include CJ HealthCare Corp, SK Chemicals Co Ltd, and Daewoong Pharmaceutical Co Ltd. Each of these companies operates in the pharmaceutical industry and offers a range of products and services that may overlap with Dongkook Pharmaceutical Co Ltd's offerings. Despite facing competition, Dongkook Pharmaceutical Co Ltd strives to differentiate itself by highlighting its unique product portfolio, innovation, and commitment to quality.

Dongkook Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

Dongkook Pharmaceutical Co Ltd operates in the healthcare sector, specifically in the pharmaceutical industry. As a company, Dongkook Pharmaceutical focuses on the research, development, manufacturing, and marketing of various pharmaceutical products. With its innovative and technology-driven approach, Dongkook Pharmaceutical aims to enhance people's quality of life by providing effective and reliable medications. The company emphasizes its commitment to research and development, striving to introduce new and improved therapeutic options for various diseases and medical conditions. With a strong focus on quality and compliance, Dongkook Pharmaceutical aims to contribute to the advancement of healthcare and the well-being of individuals globally.

Dongkook Pharmaceutical Co KGV ir 12,30.

Dongkook Pharmaceutical Co KUV ir 1,00.

AlleAktien kvalitātes vērtējums Dongkook Pharmaceutical Co ir 7/10.

gaidāmā Dongkook Pharmaceutical Co apgrozījums ir 813,32 miljardi KRW.

gaidāmā Dongkook Pharmaceutical Co peļņa ir 66,29 miljardi KRW.

Dongkook Pharmaceutical Co Ltd is a Korean company that specializes in the production and distribution of pharmaceuticals and medical devices. The company was founded in 1968 and is headquartered in Seoul, South Korea. Dongkook Pharmaceutical Co Ltd is a publicly traded company and is one of the largest pharmaceutical companies in Korea. The company is divided into three main sectors: pharmaceuticals, medical devices, and healthcare. Each of these divisions offers a range of products specifically tailored to the needs and requirements of customers. In the pharmaceuticals sector, Dongkook offers various products for the treatment of conditions such as hypertension, diabetes, asthma, allergies, and pain. The product range includes tablets, drops, sprays, ointments, injections, and high-quality biological medicines. In the medical devices sector, Dongkook offers high-quality devices and instruments used in medicine. These include blood pressure monitors, stethoscopes, ultrasound machines, endoscopes, and ventilators. These products are distributed to both hospitals and medical facilities, as well as individual customers. In the healthcare sector, Dongkook offers various dietary supplements, vitamins, and cosmetics. These products contribute to improving the health and well-being of customers. This includes multivitamin and mineral supplements, omega-3 and other dietary supplements, as well as skincare and haircare products. Dongkook Pharmaceutical Co Ltd's business model is based on high-quality products and excellent customer care. The company works closely with customers and partners to ensure that products meet their needs and requirements. The company employs highly qualified researchers and professionals who constantly work on developing new products and driving innovation. Dongkook Pharmaceutical Co Ltd aims to play a leading role in the global pharmaceutical industry. The company actively participates in international collaborations and partnerships to optimize the distribution and marketing of its products worldwide. The company has branches and distribution partners in Asia, Europe, North America, and other regions of the world. In conclusion, Dongkook Pharmaceutical Co Ltd is a leading company in the pharmaceutical industry, offering a wide range of pharmaceuticals, medical devices, and healthcare products to customers worldwide. The company relies on high quality and innovation to satisfy its customers and secure its leading position in the global pharmaceutical industry.

Dongkook Pharmaceutical Co izmaksā dividendes 180,00 KRW, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Dongkook Pharmaceutical Co vai uzņēmums nedod dividendes.

Dongkook Pharmaceutical Co ISIN ir KR7086450004.

Dongkook Pharmaceutical Co simbols ir 086450.KQ.

Pēdējo 12 mēnešu laikā Dongkook Pharmaceutical Co maksāja dividendes 180,00 KRW apmērā. Tas atbilst aptuveni 0,99 % dividendes ražībai. Nākamajos 12 mēnešos Dongkook Pharmaceutical Co plāno maksāt dividendes 196,06 KRW apmērā.

Dongkook Pharmaceutical Co pašreizējā dividendu rentabilitāte ir 0,99 %.

Dongkook Pharmaceutical Co maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos janvāris, janvāris, janvāris, janvāris.

Dongkook Pharmaceutical Co pēdējo 15 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 196,06 KRW. Tas atbilst dividendes ražībai 1,08 %.

Dongkook Pharmaceutical Co tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Dongkook Pharmaceutical Co apmērā 180 KRW, kas tika izmaksāta 19.04.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 27.12.2023..

Pēdējās dividendes izmaksa notika 19.04.2024..

Gadā 2023, Dongkook Pharmaceutical Co izmaksāja 180 KRW dividendes.

Dongkook Pharmaceutical Co dividendes tiek izmaksātas KRW.